Gossamer Bio, Inc. (NASDAQ: GOSS), a biopharmaceutical firm focused on treatments for pulmonary hypertension, has disclosed early results from its exchange offer for existing convertible notes. As of June 2, 2026, the company reported that $181,052,000 in convertible notes were validly tendered, accounting for 90.526% of the outstanding notes. In a significant move, Gossamer amended the minimum tender condition from 98% to 90.5%, allowing for the acceptance of these early tendered notes. The early settlement date is set for June 4, 2026, where participants will receive new 7.50% convertible notes, shares of common stock, and purchase warrants. The exchange offer is open until June 16, 2026, unless extended. Gossamer aims to eliminate restrictive covenants in the existing notes' indenture through this exchange, which is expected to enhance its financial flexibility.